Reprogramming human T cell function and specificity with non-viral genome targeting
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro bench research using primary human cells
OpenAlex W3104506918 · doi:10.1101/183418
What was done
Researchers developed a non-viral CRISPR-Cas9 genome targeting method to insert large (>1 kilobase) DNA sequences into specific genomic sites via homology-directed repair in primary human T cells. The approach was evaluated in two preclinical models: correcting a pathogenic IL2RA mutation in primary T cells from family members with a monogenic autoimmune disorder, and replacing the endogenous T cell receptor (TCR) locus with a cancer-antigen-specific TCR to assess tumor recognition, cytokine release, and tumor cell killing in vitro.
What was found
The abstract reports successful site-specific insertion of individual and multiplexed large DNA sequences while maintaining cell viability and function. In the autoimmune model, IL2RA gene correction enhanced downstream signaling function. In the oncology model, replacement of the endogenous TCR redirected T cells to specifically recognize cancer antigens, stimulate cytokine release, and kill target tumor cells. The abstract does not provide numerical values or efficiency percentages.
Why it matters
This non-viral genome editing strategy bypasses the complex, costly, and time-intensive manufacturing requirements of recombinant viral vectors while enabling targeted, large-fragment DNA knock-ins in primary human T cells for cell-based immunotherapies.
Limits
The abstract reports purely in vitro preclinical laboratory experiments and provides no quantitative metrics regarding editing efficiency, off-target rates, insertion fidelity, or overall cell yield. Long-term safety, potential genotoxicity, in vivo persistence, and therapeutic efficacy in animal models or human clinical trials were not evaluated.
Cited by
- supports CRISPR-mediated genome editing can insert large synthetic DNA sequences spanning hundreds to thousands of nucleotides into targeted genomic sites in primary human T cells.